Bonerge Lifescience to Debut BonFusion and BonVesio Delivery Platforms at SupplySide Global 2026

Bonerge Lifescience announced BonFusion and BonVesio, two technology platforms for poorly water-soluble nutritional ingredients, and will introduce them at SupplySide Global 2026 in Las Vegas from October 28 to 30 at Booth 7911-2, Business Wire reported. The platforms target urolithin A, fisetin and S-equol.

How BonFusion and BonVesio Work

BonFusion evaluates the physicochemical properties and formulation challenges of individual ingredients to guide the selection and integration of complementary delivery technologies. For urolithin A and fisetin, the platform incorporates the ingredients into lipid-based submicron dispersions designed to improve aqueous dispersibility and dissolution performance. Target particle sizes are approximately 200-300 nm, with formulations being developed for capsules, tablets, sachets, oral liquids and beverages.

In a preclinical pharmacokinetic study, BonFusion water-dispersible urolithin A demonstrated threefold higher bioavailability than conventional urolithin A powder. BonVesio specializes in liposomal delivery systems and emphasizes the characterization of critical quality attributes. One application is BonVesio liposomal S-equol, a bioactive metabolite of the soy isoflavone daidzein that presents formulation challenges related to its limited aqueous solubility. The formulation features an encapsulation efficiency above 85%, with a particle size of 100-200 nm and a polydispersity index below 0.2.

"Delivery performance should be evaluated through measurable parameters and appropriate supporting data," said Orin Chou, R&D Director of Bonerge Lifescience. "Through BonFusion and BonVesio, we aim to give our partners a more systematic approach to formulation development, from selecting suitable delivery technologies to characterizing the resulting systems."

Bonerge invites supplement brands, formulators and ingredient buyers to visit Booth 7911-2 to explore the two platforms, review supporting formulation data and discuss opportunities for next-generation nutritional products.

Bonerge's Regulatory and Clinical Record

According to akta.pro company records, Bonerge Lifescience is a privately held B2B ingredient manufacturer producing proprietary branded nutraceutical and cosmeceutical actives, including fisetin, urolithin A, S-equol and dihydroberberine, for global supplement and cosmetic brand manufacturers, supported by ODM and CDMO services. The company was founded in 2022 and is headquartered in Changsha, China, with a headcount range of 11-50, a revenue estimate of $10 million-$25 million and a valuation estimate of $10 million-$50 million.

The same records show EquoYouth S-Equol became the first SA-GRAS certified, 100% natural S-Equol in December 2025, securing U.S. regulatory positioning for the women's hormonal health ingredient. BeFisetin achieved Self-Affirmed GRAS status in the United States in April 2025, becoming the world's first all-natural fisetin ingredient with GRAS certification at >98% HPLC purity. In December 2024, Bonerge initiated a 108-participant clinical trial evaluating fisetin, urolithin A and ergothioneine for skin and organ rejuvenation, expected to conclude March 2026.

SupplySide Global 2026 Dates

SupplySide Global 2026 runs from October 28 to 30 in Las Vegas, where Bonerge will present the platforms at Booth 7911-2. The company's 108-participant clinical trial evaluating fisetin, urolithin A and ergothioneine for skin and organ rejuvenation is expected to conclude in March 2026.